OncoMatch/Clinical Trials/NCT05776524
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
Is NCT05776524 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Nab paclitaxel and Gemcitabine for pancreatic cancer.
Treatment: Nab paclitaxel · Gemcitabine · TheraBionic — The objective of this research is to find out what effects (good and bad), the combination of gemcitabine and nab-paclitaxel therapy (GEM-ABR for the rest of the document), standard chemotherapy for pancreatic cancer, and the TheraBionic device has on participants' condition.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage IV
Excluded: Stage LOCALIZED RESECTABLE, III
Metastatic disease required
newly diagnosed untreated biopsy proven metastatic adenocarcinoma of the pancreas
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Exception: FOLFIRINOX in adjuvant or neoadjuvant setting allowed
Patients treated with any chemotherapy in metastatic setting and/or who had chemotherapy with gemcitabine and/or nab-paclitaxel within six months prior to entering the study in the adjuvant or neo-adjuvant setting are excluded. Patients who have had chemotherapy with FOLFIRINOX prior to entering the study in the adjuvant or neo-adjuvant setting can be enrolled into the study.
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1,500/mcL; Platelets ≥ 100,000/mcL; Hemoglobin ≥ 7 g/dL (transfusion allowed to meet criteria)
Kidney function
Creatinine ≤ 1.5 X institutional upper limit of normal OR CrCL > 50
Liver function
Total bilirubin ≤ 1.5 X institutional upper limit of normal; AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional upper limit of normal (≤ 5 x ULN, if liver metastasis)
Patients must have organ and marrow function as defined below: Absolute neutrophil count (ANC) ≥ 1,500/mcL Platelets ≥ 100,000/mcL Hemoglobin ≥ 7 g/dL (transfusion allowed to meet criteria). Total bilirubin ≤ 1.5 X institutional upper limit of normal AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional upper limit of normal (≤ 5 x ULN, if liver metastasis) Creatinine ≤ 1.5 X institutional upper limit of normal Or CrCL > 50
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify